A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenous TP-271 in Healthy Adult Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2018
At a glance
- Drugs TP 271 (Primary)
- Indications Bacterial infections; Community-acquired pneumonia
- Focus Adverse reactions
- Sponsors Tetraphase Pharmaceuticals
- 08 Nov 2018 According to a Tetraphase Pharmaceuticals media release, this study is expected to complete in 2Q 2019.
- 18 Oct 2018 Planned End Date changed from 31 Oct 2018 to 28 Feb 2019.
- 18 Oct 2018 Planned primary completion date changed from 30 Sep 2018 to 31 Oct 2018.